Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2018 09:00 ET | Source: Mateon Therapeutics

Mateon Therapeutics to Present at the Rodman & Renshaw Investor Conference on September 6, 2018

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing drugs for the treatment of orphan oncology indications,...
August 17, 2018 08:50 ET | Source: Mateon Therapeutics

Mateon Therapeutics Receives Notice of Partial Clinical Hold for OX1222 Study

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
August 14, 2018 16:25 ET | Source: Mateon Therapeutics

Mateon Therapeutics Reports Second Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
May 14, 2018 07:45 ET | Source: Mateon Therapeutics

Mateon Therapeutics Reports First Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
April 16, 2018 16:35 ET | Source: Mateon Therapeutics

Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
April 16, 2018 16:10 ET | Source: Mateon Therapeutics

Mateon Therapeutics Raises Net Proceeds of Approximately $2.4 Million in Financing Transaction

SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
January 08, 2018 07:15 ET | Source: Mateon Therapeutics

Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors

· CA4P and checkpoint inhibitor combination nearly doubles amount of tumor necrosis SOUTH SAN FRANCISCO, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a...
January 03, 2018 07:30 ET | Source: Mateon Therapeutics

Mateon Therapeutics to Present at the 2018 Biotech Showcase

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
December 05, 2017 08:45 ET | Source: Mateon Therapeutics

Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor

Addition of CA4P simultaneously reduces tumor volume and increases tumor white blood cells, T Cells and cytotoxic T Cells compared to anti-CTLA-4 monotherapyPreliminary data suggest immuno-oncology...
November 14, 2017 08:00 ET | Source: Mateon Therapeutics

Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right